Shire Opts Not To Sue Teva Over Adderall XR ANDA

Law360, New York (April 12, 2005, 12:00 AM EDT) -- Shire Pharmaceuticals Group has decided not to sue Israeli generics maker Teva Pharmaceuticals USA Inc. over its application for a generic version of the best-selling attention deficit drug Adderall XR.

In February, Shire said that it had received a Paragraph IV Notice letter from Teva advising of the filing of an Abbreviated New Drug Application for its amphetamine combination product, a generic version of Shire's Adderall XR, a mixed amphetamine salts product.

Shire has filed lawsuits against generics makers Barr Laboratories and Impax, the first two...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.